Aclaris Therapeutics

Aclaris Therapeutics Announces Promising Phase 2b Results for ATI-1777, Boosting Investor Confidence

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has released promising top-line results from its Phase 2b study of ATI-1777, a topical “soft” JAK 1/3 inhibitor developed for treating mild …

Aclaris Therapeutics Announces Promising Phase 2b Results for ATI-1777, Boosting Investor Confidence Read More

Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Achieves Milestone in Phase 2 Trial of Groundbreaking Skin Cancer Therapy

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leader in dermatology therapeutics, announced a significant development in its ongoing research for innovative skin cancer treatments. The company confirmed …

Verrica Pharmaceuticals Achieves Milestone in Phase 2 Trial of Groundbreaking Skin Cancer Therapy Read More


Immunome

Immunome Set to Acquire Atreca’s Antibody-Related Assets in a Move to Revolutionize Cancer Therapies

EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a leading biotech firm specializing in cancer therapies, recently announced its plan to purchase a trove of antibody-related assets from Atreca, Inc. (Nasdaq: …

Immunome Set to Acquire Atreca’s Antibody-Related Assets in a Move to Revolutionize Cancer Therapies Read More